

Price Sensitive Information

The Meeting of the Board of Directors of Beacon Pharmaceuticals Limited held on 27th April, 2019 at 3.30 pm at its Corporate Office, BEACON Business Centre, 9/B/2, Toyenbee Circular Road, Motijheel C/A, Dhaka-1223 to adopt the 3rd quarter un-audited Financial Statements of the Company for the period ended 31st March, 2019 and has taken the following decisions:

1) Financial Information:

Earning Per Share (EPS) : Tk. 0.56
Net asset Value per share (NAVPS) : Tk. 12.95
Net operating cash flow per share (NOCFPS) : Tk. 0.79

2) The Comparative statement of financial information:

Particulars	Jul'18-Mar'19	Jul'17-Mar'18	Jan'19-Mar'19	Jan'19-Mar'19
Earning Per Share (EPS)	Tk. 0.56	Tk. 0.35	Tk. 0.21	Tk. 0.14
Net asset Value per share (NAVPS)	Tk. 12.95	Tk. 12.79	Tk. 12.95	Tk. 12.79
Net operating cash flow per share (NOCFPS)	Tk. 0.79	Tk. 1.97	Tk. 0.79	Tk. 1.97

Date : 28.04.2019

By the order of the Board of Directors



BEACON[®]
Pharmaceuticals Limited
BEACON Business Centre:
9/B/2 Toyenbee Circular Road, Motijheel, Dhaka-1223

A handwritten signature in black ink, likely belonging to Giash Uddin Ahmed.

Giash Uddin Ahmed FCMA
Company Secretary

3C X 4 Inch